Eiko Lifesciences Reports Mixed Financial Results Amid Sales Decline in May 2025

Eiko Lifesciences, a microcap company in the Finance/NBFC sector, has released its financial results for the quarter ending March 2025, with the announcement made on May 14, 2025. The company has experienced a notable adjustment in its evaluation, with its score declining from 3 to 2 over the past three months. The financial results reveal some positive aspects for Eiko Lifesciences. The Profit Before Tax (PBT) reached Rs 0.33 crore, marking the highest figure in the last five quarters, indicating a favorable near-term trend. Similarly, the Profit After Tax (PAT) also peaked at Rs 0.64 crore, reflecting an upward trajectory in profitability. Additionally, the Earnings per Share (EPS) stood at Rs 0.65, the highest in the past five quarters, suggesting enhanced earnings for shareholders. Conversely, the company faced challenges as its Net Sales for the quarter amounted to Rs 7.09 crore, which represents a decline of 15.60% year-on-year. This aspect indicates a very negative near-term sales trend. For more insights on Eiko Lifesciences and its financial performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.